Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer (MT110-101)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Amgen Research (Munich) GmbH
ClinicalTrials.gov Identifier:
NCT00635596
First received: March 7, 2008
Last updated: January 22, 2014
Last verified: January 2014

March 7, 2008
January 22, 2014
March 2008
January 2014   (final data collection date for primary outcome measure)
Overall frequency and intensity of adverse events (AEs) (clinical symptoms, laboratory abnormalities, serious adverse events [SAEs] and dose-limiting toxicities) [ Time Frame: one or more treatment cycles ] [ Designated as safety issue: Yes ]
Overall frequency and intensity of adverse events (AEs) (clinical symptoms, laboratory abnormalities, serious adverse events (SAEs) and dose-limiting toxicities) [ Time Frame: one or more treatment cycles ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00635596 on ClinicalTrials.gov Archive Site
Pharmacokinetics of MT110; T-cell counts, kinetics, and activation status; Serum cytokine concentrations; Immunogenicity; Anti-tumor activity; Other progressive disease (PD) parameters [ Time Frame: one or more treatment cycles ] [ Designated as safety issue: Yes ]
Pharmacokinetics of MT110; T-cell counts, kinetics, and activation status; Serum cytokine concentrations; Immunogenicity; Anti-tumor activity; Other PD parameters [ Time Frame: one or more treatment cycles ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
An Open-label, Multi-center Dose Escalation Phase I Study to Investigate the Safety and Tolerability of a Continuous Infusion of the Bispecific T-cell Engager (BiTE) MT110 in Locally Advanced, Recurrent or Metastatic Solid Tumors Which Commonly Express EpCAM and Are Not Amenable to Curative Treatment

This phase I dose escalation study is intended to define the safety, tolerability and maximal tolerable dose (MTD) of MT110 in patients with advanced solid tumors.

MT110 is a bispecific (anti-EpCAM x anti-CD3) T-cell engager (BiTE) designed to link EpCAM (epithelial cell adhesion molecule) expressing cells and T-cells resulting in T-cell activation and a cytotoxic T-cell response against EpCAM+ cells. In vitro and ex-vivo data indicate that EpCAM+ tumor cell lines are sensitive to MT110 mediated cytotoxicity. Furthermore, data from in-vivo experiments with both MT110 and a mouse surrogate molecule (muS110) have confirmed the activity of these molecules in inhibiting the formation of metastases but also against established tumors. In vitro and ex-vivo data suggest that a prolonged presence of the drug in target tissues may result in significant T-cell recruitment, activation and expansion to/in target tissues, potentially resulting in substantial anti-tumor activity in man.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Solid Tumors
Biological: MT110
MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
Other Name: bispecific T-cell engager (BiTE)
Experimental: I
Intervention: Biological: MT110
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
70
April 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Locally advanced, recurrent or metastatic solid tumors known to widely express EpCAM and proven histology of the following entities:

    • Adenocarcinoma of the lung
    • Small cell lung cancer (SCLC)
    • Gastric cancer or adenocarcinoma of gastro-esophageal junction
    • Colorectal cancer (CRC)
    • Hormone-refractory prostate cancer (HRPC)
    • Breast cancer
    • Ovarian cancer

    Patients must not be amenable to curative therapy. Patients should have exhausted or declined standard therapeutic options and previous therapies should have included at least one course of chemotherapy.

  2. Non-measurable disease or at least one measurable tumor lesion as per RECIST criteria
  3. Age >/= 18 years
  4. ECOG performance status </= 2
  5. Life expectancy of at least 3 months
  6. Must have recovered from the acute reversible effects of previous anti-cancer chemotherapy, endocrine therapy, immunotherapy, radiotherapy or surgery.

    • This generally means at least 4 weeks since major surgery, radical radiotherapy or myelosuppressive chemotherapy (6 weeks for nitrosoureas or mitomycin C).
    • At least 4-5 half-lives (t1/2) must have elapsed since treatment with an investigational agent.
    • At least 4 weeks since any hormonal therapy (except LHRH agonists for patients with HRPC) prior to initiating MT110 treatment.
  7. Ability to understand the patient information and informed consent form
  8. Signed and dated written informed consent

Exclusion Criteria:

  1. Evidence of central nervous system (CNS) metastases on baseline computer tomography (CT) or magnetic resonance imaging (MRI) scan (mandatory for all patients), current or past relevant history of other CNS pathology (except migraine, headache and minor incidental findings in the MRI without any clinical manifestation within the last five years). All minor incidental findings should be discussed with the Sponsor's Medical Monitor).
  2. Neutrophil count < 1,500/mm3 (= 1.5 x 10^9/l)
  3. Platelet count < 100,000/mm3 (= 100 x 10^9/l)
  4. White blood cells (WBC) < 3 x10^9/l
  5. Hemoglobin < 9.0 g/dl
  6. Abnormal renal or hepatic function as defined below:

    • Alkaline phosphatase (AP)>/= 2.5 x upper limit of normal (ULN) and/or aspartate aminotransferase (AST, SGOT), alanin aminotransferase (ALT, SGPT) >/= 2.0 x ULN or AP, AST and/or ALT >/= 3 x ULN in case of liver metastases; γ-glutamyl transpeptidase (GGT) >/= 5.0 x ULN
    • Total bilirubin >/= 1.5 x ULN
    • Creatinine clearance < 50 ml/min calculated by the Cockroft-Gault formula or MDRD (modification of diet in renal disease)
    • Lipase/amylase > 1.5 x ULN
    • D-dimer >/= 10 x ULN
    • Antithrombin activity < 70%
    • International normalized ratio (INR) > ULN
    • Partial thromboplastin time (PTT) > ULN
  7. Oxygen (O2) saturation of < 92% (under room air condition)
  8. Any concurrent anti-neoplastic therapy with the exception of radiotherapy for palliation of symptoms after agreement by the Sponsor's Medical Monitor. No radiation is allowed for defined measurable lesions according to RECIST. Patients with HRPC who have received LHRH-agonist therapy for >1 month, should continue agonist therapy.
  9. Any concurrent disease, medical or social condition that could affect compliance with the protocol or interpretation of results as judged by the investigator. In particular, patients with the following conditions are not allowed to enter the study:

    • Autoimmune and inflammatory diseases including vasculitis, rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis and similar conditions
    • Active infection or known bacteremia
    • Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus
    • Severe dyspnea or pulmonary dysfunction or need for continuous supportive oxygen inhalation
    • Insufficient cardiac function defined as NYHA (New York Heart Association) Grade 3 or 4
    • History of acute or chronic pancreatitis
  10. Chronic systemic corticosteroid therapy longer than 2 months or any other immunosuppressive therapies or stem-cell transplantation.
  11. Presence of human anti-murine antibodies (HAMA) or known hypersensitivity to immunoglobulins or to other ingredients of the infusion solution.
  12. Pregnant, nursing women or women of childbearing potential who are not willing to use effective forms of contraception during participation in the study and at least three months thereafter.
  13. Male patients with partners of child-bearing potential who are not willing to use effective contraception during the trial and for at least three months thereafter, unless surgically sterile.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00635596
MT110-101, EUDRACT No: 2007-004437-42
Yes
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Not Provided
Principal Investigator: Walter Fiedler, MD, Prof. Universitätsklinikum Hamburg-Eppendorf
Amgen Research (Munich) GmbH
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP